In vitro effect of α1-acid glycoprotein on the anti-human lmmunodeficiency virus (HIV) activity of the protease inhibitor CGP 61755: A comparative study with other relevant HIV protease inhibitors

Journal of Infectious Diseases

Volumn 175, Issue 5, 1997, Pages 1063-1070

  Lazdins, Janis K ^a   Mestan, Jürgen ^a   Goutte, Gerard ^a   Walker, Maja R ^a   Bold, Guido ^a   Capraro, Hans Georg ^a   Klimkait, Thomas ^a  

^a CIBA GEIGY LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; INDINAVIR; LASINAVIR; OROSOMUCOID; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; TELINAVIR; UNCLASSIFIED DRUG; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CARBAMIC ACID DERIVATIVE; DRUG DERIVATIVE; ETHYLENE DERIVATIVE; SULFONAMIDE; UREA;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG PROTEIN BINDING; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; LYMPHOCYTE; PRIORITY JOURNAL; CELL CULTURE; CELL LINE; COMPARATIVE STUDY; DRUG EFFECT; IMMUNOLOGY; KINETICS; PHYSIOLOGY; SERODIAGNOSIS; VIROLOGY; VIRUS REPLICATION;

ANTI-HIV AGENTS; CARBAMATES; CELL LINE; CELLS, CULTURED; ETHYLENES; HIV PROTEASE INHIBITORS; HIV SERONEGATIVITY; HIV-1; HUMANS; INDINAVIR; KINETICS; LYMPHOCYTES; OROSOMUCOID; RITONAVIR; SAQUINAVIR; SULFONAMIDES; UREA; VIRUS REPLICATION;

EID: 0030610689     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/520352     Document Type: Article

References (15)

1. Danner SA, Carr A, Leonard JM, et al. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. N Engl J Med 1995;333:1528-33.
2. Wei X, Ghosh SK, Taylor ME, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995;373:117-22.
3. Kitchen VS, Skinner C, Ariyoshi K, et al. Safety and activity of saquinavir in HIV infection. Lancet 1995;345:952-5.
4. Capraro HG, Bold G, Fässler A, et al. Synthesis of potent and orally active HIV-protease inhibitors. Arch Pharm Pharmacol Med Chem 1996;392:273-8.
5. Cozens RM, Bold G, Capraro HG, et al. Synthesis and pharmacological evaluation of CGP 57813 and CGP 61755, HIV-1 protease inhibitors from the Phe-c-Phe peptidomimetic class. Antiviral Chem Chemother 1996;7:294-9.
6. Kempf DJ, Marsh KV, Denissen JF, et al. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc Natl Acad Sci USA 1995;92:248-8.
7. Invirase. In: Morant J, Ruppanner H, eds. Compendium Suisse des mèdicaments. Basel: Documed, 1996; supplementum 3:35-7.
8. Bryant M, Getman D, Smidt M, et al. SC-52151, a novel inhibitor of the human immunodeficiency virus protease. Antimicrob Agents Chemother 1995;391:2229-34.
9. Sommadossi JP, Schinazi RF, McMillan A, Xie MY, Bryant M. A human serum glycoprotein profoundly affects antiviral activity of the protease inhibitor SC-52151 by decreasing its cellular uptake abstract LB4. In: Program and abstracts of the 2nd National Conference on Human Retroviruses and Related Infections (Washington, DC). Washington, DC: American Society for Microbiology, 1995.
10. Oie S, Jacobson MA, Abrams DI. Alpha 1-acid glycoprotein levels in AIDS patients before and after short-term treatment with zidovudine (ZDV). J Acquir Immune Defic Syndr 1993;6:531-3.
11. 1-acid glycoprotein is reduced in HIV-infected patients co-infected with hepatitis C virus (HCV) [abstract 170]. In: Program and abstracts of the 3rd Conference on Retroviruses and Opportunistic Infections (Washington, DC). Alexandria, VA: Infectious Diseases Society of America for the Foundation for Retrovirology and Human Health, 1996:84.
12. Bilello JA, Bilello PA, Sharry MC, et al. Plasma protein binding to A-80987, an inhibitor of the HIV-1 protease, in patients with AIDS and opportunistic infection [abstract 132]. In: Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco). Washington, DC: American Society for Microbiology, 1995:211.
13. Lazdins JK, Woods-Cook K, Walker M, Alteri E. The lipophilic muramyl peptide MTP-PE is a potent inhibitor of HIV replication in macrophages. AIDS Res Hum Retroviruses 1990;6:1157-61.
14. Barre-Sinoussi F, Chermann JC, Rey F, et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983;220:868-71.
15. Haertle T, Carrera CJ, Wasson DB, Sowers LC, Richman DD, Carson DA. Metabolism and anti-human immunodeficiency virus-1 activity of 2-halo-2′,3′-dideoxyadenosine derivatives. J Biol Chem 1988;263:5870-5.